1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
ALTEOGEN Inc.

ALTEOGEN Inc.

KKRX:196170
231,000.00
KRW
-9,000.00
(-3.75%)
1,905.78EPS
140.20P/E
18.27TMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
255.18
184.24
86.09
121.42
207.26
231.78
230.49
432.02
490.81
432.51
1,431.34
1,489.54
3,109.55
2,932.58
Basic EPS, GAAP
74.15
24.36
22.01
-63.64
-127.55
-116.24
-5.56
-161.11
-79.49
-122.31
-50
901.54
2,040.77
1,873.67
Free Cash Flow per Basic Share
64.52
29.43
-30.17
-101.35
-87.87
-278.94
6.34
-40.89
-424.82
-906.37
-715.34
414.15
1,306.72
1,530.73
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
116.2
686
697.5
776.54
675.15
1,116.78
1,076.04
930.48
2,030.07
2,215.46
2,150.18
3,948.89
6,403.21
7,242.06
Tangible Book Value per Share
115.19
684.14
694.22
740.35
664.97
1,106.29
1,064.61
914.96
1,858.1
1,508.89
853.36
2,330.34
4,675.54
5,540.9
Basic Weighted Avg Shares
22
38
55
56
58
59
127
98
79
67
67
69
69
69
Sales/Revenue/Turnover
5,527
7,043
4,727
6,844
12,104
13,703
29,229
42,426
38,746
28,806
96,523
102,855
215,859
203,761
Operating Margin (%)
27.33
10.28
2.62
-79.07
-51
-55.9
-7.7
-0.14
-39.21
-101.97
-10.09
24.7
49.52
41.81
Depreciation Expense
127
166
214
352
423
553
972
1,869
2,151
2,654
3,334
2,850
5,489
7,728
Net Income, GAAP
1,606
931
1,208
-3,587
-7,449
-6,872
-705
-15,822
-6,275
-8,146
-3,372
62,252
141,666
130,187
Effective Tax Rate (%)
0.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.79
27.62
Profit Margin (%)
29.06
13.22
25.57
-52.42
-61.54
-50.15
-2.41
-37.29
-16.2
-28.28
-3.49
60.52
65.63
63.89
Working Capital
6,757
23,361
26,241
37,119
32,975
55,781
53,837
40,865
87,487
50,787
43,660
82,599
241,111
299,105
LT Debt
1,144
- -
- -
- -
- -
1,500
1,052
772
1,065
778
1,413
5,091
4,152
3,750
Total Equity
6,039
35,825
38,551
45,229
39,845
66,696
70,204
60,582
131,527
145,382
147,842
274,091
454,443
512,858
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
26.14
13.57
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.59
30.04
Return on Common Equity (%)
- -
4.45
3.25
-8.56
-17.51
-12.98
-1.04
-24.13
-6.43
-5.77
-2.27
29.52
39.42
29.86

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,480
2,907
3,362
LT Borrowings
4,444
4,028
3,611
LT Finance Leases
251
124
139
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
24,494,793
24,040,195
18,273,711

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
441,772
480,795
511,501
Cash, Cash Equivalents & STI
379,768
430,022
447,625
Accounts Receivable, Net
42,949
4,808
- -
Inventories
6,692
6,530
6,197
Total Current Liabilities
256,390
239,684
212,396
Payables & Accruals
- -
- -
- -
ST Debt
2,480
2,907
3,362
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.49%
56.1%
65.8%
Free Cash Flow
60.48%
170.59%
217.19%
Net Income, GAAP
-14.88%
-381.57%
127.57%
Sales/Revenue/Turnover
61.05%
63.44%
109.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,901
12,234
4,890
50,830
102,855
2025
83,696
18,643
49,013
64,507
215,859
2026
71,599
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
304.62
-42.31
-134.62
772.2
901.54
2025
1,200.77
-477
321.59
995.85
2,040.77
2026
1,031.02
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tae-Yon Chun
Full Time Employees
161
Sector
Health technology
Industry
Biotechnology
Address
62, Yuseong-daero Daejeon DE South Korea 34054
IPO Date
Dec 12, 2014
Website
alteogen.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
ALTEOGEN Inc. ALTEOGEN Inc. (196170.KQ), a South Korea-based biopharmaceutical company founded in 2008 and headquartered in Daejeon, develops long-acting biobetters, proprietary antibody-drug conjugates, and complex antibody biosimilars utilizing its proprietary NexP platform for protein fusion technology, NexMab for antibody-drug conjugate manufacturing, and Hybrozyme for recombinant human hyaluronidase-based subcutaneous delivery; its pipeline includes ALT-P1, a long-acting human growth hormone in Phase IIa trials for growth hormone deficiency; ALT-Q2, a long-acting coagulation factor VIIa in development for hemophilia; ALT-P7, a Phase I targeted therapy for breast and gastric cancer; ALT-Q5, an antibody-drug conjugate for ovarian cancer; ALT-LS2, a subcutaneous trastuzumab formulation for breast and gastric cancer; ALT-L9, an Eylea (aflibercept) biosimilar in Phase III for wet age-related macular degeneration; and ALT-L2, a Herceptin (trastuzumab) biosimilar in Phase II for breast cancer, with partnerships including Kissei Pharmaceutical for ALT-L9 and Cristalia for ALT-L2. The company targets global markets in oncology, endocrinology, ophthalmology, and hematology, primarily serving pharmaceutical partners and end-users through technology licensing, joint development, and biosimilar commercialization in regions including Asia, Europe, and the Americas. In recent developments, ALTEOGEN Inc. secured a landmark partnership with AstraZeneca in March 2025 valued at up to $1.35 billion across two contracts for its ALT-B4 hyaluronidase (Hybrozyme) technology to enable subcutaneous formulations of multiple oncology assets; entered a collaboration with Daiichi Sankyo for subcutaneous Enhertu; received European Commission approval in September 2025 for Eyluxvi (ALT-L9), its second biosimilar launch following Herceptin in China via partner Qilu; and maintains ongoing alliances with Merck for Keytruda subcutaneous formulations and other top global pharmas for hyaluronidase applications.